Amarin Corp. ADR sell JPMorgan Chase & Co.
Start price
20.11.23
/
50%
€0.72
Target price
20.11.24
-
Performance (%)
9.72%
Price
26.04.24
€0.82
Summary
This prediction is currently active. With a performance of 9.72%, the SELL prediction by JPMorgan_Chase___Co_ for Amarin Corp. ADR is trending in the wrong direction This prediction currently runs until 20.11.24. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionAmarin Corporation plc (Symbol AMRN) is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's main product, Vascepa, is a prescription medication that has been approved by the US FDA for use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa has also shown to reduce the risk of cardiovascular events such as heart attack and stroke in patients with elevated cardiovascular risk. As a listed company, Amarin is publicly traded on the NASDAQ stock exchange and has a market capitalization of approximately $5 billion as of August 2021.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Amarin Corp. ADR | -1.212% | -1.212% |
| iShares Core DAX® | 2.594% | -1.158% |
| iShares Nasdaq 100 | 3.553% | -1.727% |
| iShares Nikkei 225® | 0.687% | -8.354% |
| iShares S&P 500 | 2.209% | -0.942% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Amarin Corp. ADR diskutieren
Amarin Co. plc (NASDAQ: AMRN) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co..
Ratings data for AMRN provided by MarketBeat